Author

Alessandro Armuzzi

Gathering intelligence to improve long-term outcomes in ulcerative colitis: new evidence (Takeda) (Complete Session)
Gathering intelligence to improve long-term outcomes in ulcerative colitis: new evidence (Takeda) (Complete Session)

Alessandro Armuzzi  et al.

REAL-LIFE EVALUATION OF GOLIMUMAB EFFECTIVENESS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: THE PROSPECTIVE GO-CARE STUDY
REAL-LIFE EVALUATION OF GOLIMUMAB EFFECTIVENESS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: THE PROSPECTIVE GO-CARE STUDY

Alessandro Armuzzi  et al.

CHARACTERISTICS AND REAL WORLD TREATMENT HISTORY OF PATIENTS TREATED WITH TOFACITINIB FOR ULCERATIVE COLITIS IN EUROPE
CHARACTERISTICS AND REAL WORLD TREATMENT HISTORY OF PATIENTS TREATED WITH TOFACITINIB FOR ULCERATIVE COLITIS IN EUROPE

Alessandro Armuzzi  et al.

OPTIMIZING THE POSITION OF VEDOLIZUMAB IN TREATMENT SEQUENCES FOR CROHN’S DISEASE: RESULTS FROM A MARKOV MODEL SIMULATION USING REAL-WORLD EVIDENCE
OPTIMIZING THE POSITION OF VEDOLIZUMAB IN TREATMENT SEQUENCES FOR CROHN’S DISEASE: RESULTS FROM A MARKOV MODEL SIMULATION USING REAL-WORLD EVIDENCE

Alessandro Armuzzi  et al.

Optimal medical and surgical treatment: When, where, who?
Optimal medical and surgical treatment: When, where, who?

Alessandro Armuzzi  et al.

CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME
CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Walk this way: navigating the evolving UC treatment pathway (Galapagos)
Walk this way: navigating the evolving UC treatment pathway (Galapagos)

Alessandro Armuzzi  et al.

Targeting IL-12/23 in ulcerative colitis: from evidence to bedside (Janssen)
Targeting IL-12/23 in ulcerative colitis: from evidence to bedside (Janssen)

Alessandro Armuzzi  et al.

OUTCOMES OF EARLY AND LATE ADVANCED THERAPY USE IN PATIENTS WITH ULCERATIVE COLITIS: FINDINGS FROM A EUROPEAN REAL-WORLD STUDY
OUTCOMES OF EARLY AND LATE ADVANCED THERAPY USE IN PATIENTS WITH ULCERATIVE COLITIS: FINDINGS FROM A EUROPEAN REAL-WORLD STUDY

Alessandro Armuzzi  et al.

Early disease control in UC and CD
Early disease control in UC and CD

Alessandro Armuzzi  et al.

Targeted oral therapies for the treatment of moderate to severe UC (Bristol Myers Squibb)
Targeted oral therapies for the treatment of moderate to severe UC (Bristol Myers Squibb)

Alessandro Armuzzi  et al.

OUTCOMES OF EARLY AND LATE ADVANCED THERAPY USE IN PATIENTS WITH ULCERATIVE COLITIS: FINDINGS FROM A EUROPEAN REAL-WORLD STUDY
OUTCOMES OF EARLY AND LATE ADVANCED THERAPY USE IN PATIENTS WITH ULCERATIVE COLITIS: FINDINGS FROM A EUROPEAN REAL-WORLD STUDY

OPTIMIZING THE POSITION OF VEDOLIZUMAB IN TREATMENT SEQUENCES FOR CROHN'S DISEASE: RESULTS FROM A MARKOV MODEL SIMULATION USING REAL-WORLD EVIDENCE
OPTIMIZING THE POSITION OF VEDOLIZUMAB IN TREATMENT SEQUENCES FOR CROHN'S DISEASE: RESULTS FROM A MARKOV MODEL SIMULATION USING REAL-WORLD EVIDENCE

Segmental colitis associated with diverticular disease
Segmental colitis associated with diverticular disease

Alessandro Armuzzi

Rescue treatments and JAK-inhibitors: A new hope ?
Rescue treatments and JAK-inhibitors: A new hope ?

Alessandro Armuzzi

REAL-LIFE EVALUATION OF GOLIMUMAB EFFECTIVENESS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: THE PROSPECTIVE GO-CARE STUDY
REAL-LIFE EVALUATION OF GOLIMUMAB EFFECTIVENESS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: THE PROSPECTIVE GO-CARE STUDY

What do UC on the horizon: exploring the emerging management options (Janssen)
What do UC on the horizon: exploring the emerging management options (Janssen)

Alessandro Armuzzi  et al.

JAK to the future: a patient-centric choice in UC (Galapagos)
JAK to the future: a patient-centric choice in UC (Galapagos)

Alessandro Armuzzi  et al.

CHARACTERISTICS AND REAL WORLD TREATMENT HISTORY OF PATIENTS TREATED WITH TOFACITINIB FOR ULCERATIVE COLITIS IN EUROPE
CHARACTERISTICS AND REAL WORLD TREATMENT HISTORY OF PATIENTS TREATED WITH TOFACITINIB FOR ULCERATIVE COLITIS IN EUROPE

A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Alessandro Armuzzi  et al.

Item 1 - 20 / 45
1
2 3